A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase
In the pembrolizumab plus chemotherapy regimen for patients with R/M HNSCC, the response in the combination phase may be associated with PFS in the maintenance phase.
Authors
- Chikashi Ishioka (ORCID: https://orcid.org/0000-0002-3023-1227)
- Sho Umegaki
- Keigo Komine (ORCID: https://orcid.org/0000-0003-2502-3666)
- Ken Saijo (ORCID: https://orcid.org/0000-0003-0179-3789)
- Masanobu Takahashi
- Yuya Yoshida (ORCID: https://orcid.org/0000-0001-8560-9760)
- Keiju Sasaki (ORCID: https://orcid.org/0000-0002-8270-2107)
- Sakura Taniguchi
- Hidekazu Shirota (ORCID: https://orcid.org/0000-0001-9154-9004)
- Kota Ouchi (ORCID: https://orcid.org/0000-0002-5572-1337)
- Ryunosuke Numakura
- Reio Ueta (ORCID: https://orcid.org/0009-0008-9429-3209)
- Yuki Kasahara
- Hiroo Imai (ORCID: https://orcid.org/0000-0002-1319-724X)
Institutions
- Tohoku University (JP)
- Tohoku University Hospital (JP)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s12672-025-02256-1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Taiho Pharmaceutical
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Bayer Yakuhin
- Daiichi Sankyo Company
- Daiichi Sankyo Europe